Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins: is there a clinical value?

C Gottstein1, U Winkler, H Bohlen

  • 1Medizinische Universitätsklinik I, Cologne, Germany.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 1, 1994
PubMed
Summary

Immunotoxins, combining targeted antibodies with toxins, offer a promising approach to cancer therapy. Second-generation immunotoxins show significant anti-tumor effects in models and early clinical trials for leukemia and lymphoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2020
Same author

Corrigendum to "Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial": Annals of Oncology 2012; 23: 1818-1825.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

[Checkpoint inhibitors in Hodgkin lymphoma].

Der Internist·2020
Same author

Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Drug targeting aims to eliminate malignant cells while sparing normal tissues.
  • Hybridoma technology enables mass production of monoclonal antibodies (MoAbs) for targeted therapies.
  • Immunotoxins link MoAbs to ribosome-damaging toxins (e.g., ricin, diphtheria toxin) for selective cancer cell destruction.

Purpose of the Study:

  • To review the development and efficacy of immunotoxins in cancer treatment.
  • To discuss the features of three main immunotoxin groups: ricin A-chain, blocked ricin, and recombinant toxins.

Main Methods:

  • Chemical linkage of monoclonal antibodies (or fragments) to potent toxins like ricin, abrin, saporin, Pseudomonas exotoxin (PE), and diphtheria toxin (DT).
  • Development of first-generation and second-generation immunotoxins with improved in vivo stability and efficacy.

Related Experiment Videos

  • Engineering of fusion toxins combining growth factors or cytokines with toxin moieties.

    • Main Results:

    • First-generation immunotoxins showed promise in vitro but limited anti-tumor effects in vivo.
    • Second-generation immunotoxins, including A-chain and blocked ricin variants, demonstrate high efficacy in animal models.
    • Early clinical trials suggest potential use of immunotoxins for leukemia and lymphoma patients.

    Conclusions:

    • Second-generation immunotoxins represent a significant advancement in targeted cancer therapy.
    • Immunotoxins hold promise for treating hematological malignancies like leukemia and lymphoma.
    • Ongoing research focuses on genetically engineered fusion toxins for enhanced therapeutic potential.